natgillin/translations-raw huggingface dataset:
Systemic corticosteroid effects including Cushing's syndrome and adrenal suppression have been reported in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate; this could also occur with other corticosteroids metabolised via the P450 3A pathway, e.g., budesonide. 
Sistemski učinci kortikosteroida, uključujući Cushingov sindrom i supresiju nadbubrežne žlijezde, zabilježeni su u bolesnika koji su primali ritonavir i inhalirali ili intranazalno primjenjivali flutikazon propionat; to se može dogoditi i s drugim kortikosteroidima koji se metaboliziraju putem P450 3A, npr., budezonidom.
Difference estimate [95% CI]d 
Približna razlika [95% CI]d
Protease inhibitors: The co-administration of REYATAZ/ritonavir and other protease inhibitors has not been studied but would be expected to increase exposure to other protease inhibitors. 
Inhibitori proteaze: Istovremena primjena lijeka REYATAZ s ritonavirom i drugih inhibitora proteaze nije ispitana, ali pretpostavlja se da bi povećala izloženost drugim inhibitorima proteaze.
Elevation in ALT levels were more frequently reported in paediatric patients in these studies than in adults. 
Povišenje vrijednosti ALT je češće prijavljeno u ovim ispitivanjima u pedijatrijskih bolesnika nego u odraslih.
The use of REYATAZ may be considered during pregnancy only if the potential benefit justifies the potential risk. 
Primjena lijeka REYATAZ može se uzeti u obzir tijekom trudnoće samo ako moguća korist opravdava mogući rizik.
The mechanism of interaction between REYATAZ/ritonavir and sofosbuvir/velpatasvir/voxilaprevir is inhibition of OATP1B, Pgp, and CYP3A. 
Mehanizam interakcije između REYATAZ/ritonavir i sofosbuvir/velpatasvir/voksilaprevir je inhibicija OATP1B, Pgp, i CYP3A.
If an oral contraceptive is administered with REYATAZ/ritonavir, it is recommended that the oral contraceptive contain at least 30 μg of ethinyloestradiol and that the patient be reminded of strict compliance with this contraceptive dosing regimen. 
Ako se oralna kontracepcija primjenjuje s lijekom REYATAZ s ritonavirom preporučje se da oralna kontracepcija sadrži najmanje 30 μg etinilestradiola i da se bolesnici istakne važnost redovitog uzimanja kontracepcije kod ovog kontracepcijskog režima.
For treatment-naive paediatric patients, 
U prethodno liječenih pedijatrijskih bolesnika,
Efficacy data observed in the 41 paediatric patients aged 6 years to less than 18 years that received REYATAZ capsules with ritonavir are presented in Table 7. 
Podaci o djelotvornosti opaženoj u 41 pedijatrijskog bolesnika u dobi od 6 godina do manje od 18 godina koji su primali REYATAZ kapsule s ritonavirom prikazani su u tablici 7.
Co-administration of REYATAZ with ritonavir at doses greater than 100 mg once daily has not been clinically evaluated. 
Istovremena primjena lijeka REYATAZ s ritonavirom u dozama višima od 100 mg jedanput na dan nije klinički procijenjena.
The efficacy of REYATAZ/ritonavir in combination with tenofovir disoproxil fumarate in treatmentexperienced patients has been demonstrated in clinical study 045 and in treatment naive patients in clinical study 138 (see sections 4.8 and 5.1). 
Djelotvornost lijeka REYATAZ s ritonavirom u kombinaciji s tenofovirdizoproksilfumaratom u prethodno liječenih bolesnika dokazana je u kliničkom ispitivanju 045, a u bolesnika koji prethodno nisu bili liječeni u kliničkom ispitivanju 138 (vidjeti dijelove 4.8 i 5.1).
Diabetic population 
Dijabetička populacija
If you accidentally take or give more REYATAZ oral powder than your doctor recommended, contact your HIV doctor at once or contact the nearest hospital for advice. 
Ako slučajno uzmete ili date više REYATAZ oralnog praška nego što je preporučio Vaš liječnik, odmah se obratite liječniku ili potražite savjet u najbližoj bolnici.
Food effect: co-administration of REYATAZ and ritonavir with food optimises the bioavailability of atazanavir. 
Utjecaj hrane: Istovremena primjena lijeka REYATAZ i ritonavira s hranom optimizira bioraspoloživost atazanavira.
Interactions between atazanavir/ritonavir and protease inhibitors, antiretroviral agents other than protease inhibitors, and other non-antiretroviral medicinal products are listed in the table below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”). 
Interakcije između atazanavira/ritonavira i inhibitora proteaze, amtiretrovirusnih lijekova koji nisu inhibitori proteaze i drugih lijekova koji nisu antiretrovirusni, navedene su u sljedećoj tablici (povišenje je označeno kao “↑”, sniženje kao “↓”, bez promjene kao “↔”).
*Ritonavir capsules, tablets or oral solution may be used. 
* Mogu se uzimati Ritonavir kapsule, tablete ili oralna otopina.
Do not use an infant bottle to give REYATAZ mixed with infant formula. 
Nemojte primjenjivati bocu za dojenče za primjenu lijeka REYATAZ pomiješanog s dojenačkom formulom.
Co-administration warrants clinical monitoring for sedation and cognitive effects. 
Istovremena primjena zahtijeva kliničko praćenje zbog sedacije i kognitivnih učinaka.
e Number of patients evaluable. 
e Broj bolesnika koje se moglo procijeniti.
Put another 10 ml of prepared infant formula in the cup or container and rinse the remaining oral powder from the cup or container. 
5. Stavite dodatnih 10 ml pripremljene dojenačke formule u čašu ili spremnik i isperite ostatak oralnog praška iz čaše ili spremnika.
MARKETING AUTHORISATION NUMBER(S) EU/1/03/267/001-006; 008-011 
BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/03/267/001-006; 008-011
Blister pack: 30 hard capsules 
Blister pakiranje: 30 tvrdih kapsula
REYATAZ with food and drink See section 3 How to take REYATAZ. 
REYATAZ s hranom i pićem Pogledajte dio 3.
b Ten patients had baseline phenotypic resistance to atazanavir + ritonavir (fold change [FC]>5.2). 
b Deset bolesnika imalo je na početku fenotipsku rezistenciju na atazanavir s ritonavirom (promjena ekspresije [FC] >5,2 puta).
REYATAZ (without ritonavir) has been studied in adult patients with severe renal impairment (n=20), including those on haemodialysis, at multiple doses of 400 mg once daily. 
REYATAZ (bez ritonavira) ispitan je u odraslih bolesnika s teškim oštećenjem funkcije bubrega (n=20), uključujući one na hemodijalizi, pomoću višestrukih doza od 400 mg jedanput na dan.
For children (at least 3 months of age and weighing at least 5 kg), your child's doctor will decide the right dose based on your child's weight. 
Za djecu (u dobi od 3 mjeseca i tjelesne težine od najmanje 5 kg), liječnik Vašeg djeteta odlučit će koja je doza ispravna na temelju tjelesne težine Vašeg djeteta.
Metabolic parameters 
Metabolički paramateri
The choice of REYATAZ in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient's treatment history (see sections 4.4 and 5.1). 
Odabir lijeka REYATAZ za liječenje već liječenih odraslih i pedijatrijskih bolesnika treba biti utemeljen na pojedinačnom testiranju virusne rezistencije i prethodnom liječenju pojedinog bolesnika (vidjeti dijelove 4.4 i 5.1).
Blister pack: 60 hard capsules 
Blister pakiranje: 60 tvrdih kapsula
Of importance, many studies were conducted with unboosted atazanavir, which is not the approved regimen of atazanavir. 
Važno je istaknuti da su mnoga ispitivanja provedena s nepojačanim atazanavirom, što nije odobren oblik liječenja atazanavirom.
If you have been told by your doctor that your child has an intolerance to some sugars, contact your doctor before giving this medicinal product to your child. 
Ako Vam je liječnik rekao da Vaše dijete ne podnosineke šećere, obratite se liječniku prije nego počnete davati svom djetetu ovaj lijek.
Other marked clinical laboratory abnormalities (Grade 3 or 4) reported in ≥ 2% of patients receiving regimens containing REYATAZ and one or more NRTIs included: elevated creatine kinase (7%), elevated alanine aminotransferase/serum glutamic-pyruvic transaminase (ALT/SGPT) (5%), low neutrophils (5%), elevated aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/SGOT) (3%), and elevated lipase (3%). 
Drugi značajni kliničko-laboratorijski poremećaji (3. ili 4. stupnja) zabilježeni u ≥ 2% bolesnika koji su primali terapijske protokole s lijekom REYATAZ i jednim ili više NRTI-jeva uključivali su: povišenu kreatin kinazu (7%), povišen omjer alanin aminotransferaze i serumske glutamin-piruvatne transaminaze (ALT/SGPT) (5%), nizak broj neutrofila (5%), povišen omjer aspartat aminotransferaze i serumske glutamat-oksaloctene transaminaze (AST/SGOT) (3%) i povišenu lipazu (3%).
Do not take sildenafil with REYATAZ when sildenafil is used for the treatment of pulmonary arterial hypertension. 
Nemojte uzimati sildenafil s lijekom REYATAZ kad se sildenafil primjenjuje za liječenje plućne arterijske hipertenzije.
There are no pharmacokinetic data available for REYATAZ with ritonavir in patients with renal insufficiency. 
Nema dostupnih farmakokinetičkih podataka za REYATAZ s ritonavirom u bolesnika s insuficijencijom bubrega.
In repeat-dose toxicity studies, conducted in mice, rats, and dogs, atazanavir-related findings were generally confined to the liver and included generally minimal to mild increases in serum bilirubin and liver enzymes, hepatocellular vacuolation and hypertrophy, and, in female mice only, hepatic singlecell necrosis. 
U ispitivanjima toksičnosti ponovljenih doza provedenih u miševa, štakora i pasa, nalazi povezani s atazanavirom općenito su bili ograničeni na jetru i uključivali su općenito minimalna do blaga povišenja serumskog bilirubina i jetrenih enzima, hepatocelularnu vakuolizaciju i hipertrofiju te, samo u ženki miša, nekrozu pojedinačnih jetrenih stanica.
Add 30 ml of the drink and mix with a spoon. 
Dodajte 30 ml pića i promiješajte žlicom
Administration of REYATAZ with ritonavir with either a light or a high-fat meal decreased the coefficient of variation of AUC and Cmax by approximately 25% compared to the fasting state. 
Primjena lijeka REYATAZ s ritonavirom uz lagani obrok ili obrok bogat mastima smanjila je koeficijent varijacije AUC i Cmax za približno 25% u usporedbi s onima natašte.
The appropriate option listed below is chosen for mixing and administration with liquid infant formula, beverage or food. 
2. Treba izabrati odgovarajući način naveden dolje, za miješanje i primjenu s tekućom dojenačkom formulom, pićem ili hranom.
Driving and using machines If you feel dizzy or lightheaded, do not drive or use machines, and contact your doctor immediately. 
Ako osjetite omaglicu ili ošamućenost, nemojte voziti ili upravljati strojevima i odmah se obratite liječniku.
Consult the dosing table for the specific formulation (see Summary of Product Characteristics for REYATAZ capsules). 
Provjerite tablicu doziranja za određenu formulaciju (vidjeti Sažetak opisa svojstava lijeka za REYTAZ kapsule).
Overall in this study, 182 paediatric patients (81 antiretroviral-naive and 101 antiretroviral-experienced) received once daily REYATAZ (capsule or powder formulation), with or without ritonavir, in combination with two NRTIs. 
U ovom su ispitivanju ukupno 182 pedijatrijska bolesnika (81 koji prethodno nisu bili liječeni i 101 prethodno liječeni antiretrovirusnim lijekovima) primala REYATAZ (kapsule ili u prašku) jedanput na dan, s ritonavirom ili bez njega, u kombinaciji s dva NRTI-ja.
Stevens-Johnson syndrome (SJS), erythema multiforme, toxic skin eruptions and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported with the use of REYATAZ (see section 4.4). 
Stevens-Johnsonov sindrom (SJS), multiformni eritem, toksične kožne erupcije i medikamentozni osip s eozinofilijom i sistemskim simptomima (DRESS) zabilježeni su kod primjene lijeka REYATAZ (vidjeti dio 4.4).
The pharmacokinetics of atazanavir exhibit a non-linear disposition. 
Farmakokinetika atazanavira pokazuje nelinearnu dispoziciju.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption should not take this medicinal product. 
Bolesnici s rijetkim nasljednim poremećajem nepodnošenja galaktoze, nedostatkom Lapp laktaze ili malapsorpcijom glukoze-galaktoze ne smiju uzimati ovaj lijek.
EXPIRY DATE EXP {MM/YYYY} 
ROK VALJANOSTI EXP{MM/GGGG}
In case of withdrawal of ritonavir from the recommended atazanavir boosted regimen (see section 4.4) The same recommendations for drug drug interactions would apply except: that co-administration is not recommended with tenofovir, boceprevir, carbamazepine, phenytoin, phenobarbital, proton pump inhibitors, and buprenorphine. 
Ako se ritonavir izostavi iz preporučenog režima liječenja atazanavirom pojačanim ritonavirom (vidjeti dio 4.4) Vrijede iste preporuke za interakcije između lijekova, osim sljedećega: Ne preporučuje se istovremena primjena s tenofovirom, boceprevirom, karbamazepinom, fenitoinom, fenobarbitalom, inhibitorima protonske pumpe i buprenorfinom.
SEDATIVES Benzodiazepines Midazolam Triazolam 
Benzodiazepini Midazolam Triazolam
The safety and efficacy of REYATAZ has not been established in patients with significant underlying liver disorders. 
Sigurnost i djelotvornost lijeka REYATAZ nije ustanovljena u bolesnika sa značajnom osnovnom bolešću jetre.
There is no specific antidote for overdose with REYATAZ. 
Ne postoji posebni antidot za predoziranje lijekom REYATAZ.
When REYATAZ/ritonavir is co-administered with either phenytoin or phenobarbital, a dose adjustment of phenytoin or phenobarbital may be required. 
Kada se REYATAZ s ritonavirom primjenjuje istodobno s fenitoinom ili fenobarbitalom, možda će biti potrebna prilagodba doze fenitoina ili fenobarbitala.
In clinical studies AI424-397 and AI424-451, paediatric patients 3 months to less than 11 years of age had a mean duration of treatment with REYATAZ oral powder of 80 weeks. 
U kliničkim ispitivanjima AI424-397 i AI424-451 u pedijatrijskih bolesnika u dobi od 3 mjeseca do manje od 11 godina, srednje trajanje liječenja REYATAZ oralnim praškom iznosilo je 80 tjedana.
Ketoconazole and itraconazole should be used cautiously with REYATAZ/ritonavir, high doses of ketoconazole and itraconazole (>200 mg/day) are not recommended. 
Ketokonazol i itrakonazol treba primjenjivati s oprezom kad se daju s lijekom REYATAZ /ritonavirom; ne preporučuju se visoke doze ketokonazola i itrakonazola (>200 mg na dan).
REYATAZ is also available in capsules for use in adults and children at least 6 years of age who weigh at least 15 kg and who are able to swallow the capsules. 
REYATAZ je također dostupan u obliku kapsula za primjenu u odraslih i djece u dobi od najmanje 6 godina, tjelesne težine od najmanje 15 kg koja su u mogućnusti progutati kapsule.
Each bottle contains 60 hard capsules. 
Jedna boca sadrži 60 tvrdih kapsula.
Antiretroviral treatment experienced adult patients In antiretroviral treatment experienced patients from Studies 009, 043, and 045, 100 isolates from patients designated as virological failures on therapy that included either atazanavir, atazanavir + ritonavir, or atazanavir + saquinavir were determined to have developed resistance to atazanavir. 
U antiretrovirusnom liječenju prethodno liječenih bolesnika u Ispitivanjima 009, 043 i 045, u 100 izolata iz bolesnika u kojih je terapija atazanavirom, atazanavirom s ritonavirom ili atazanavirom sa sakvinavirom bila virološki neuspješna utvrđeno je da se razvila rezistencija na atazanavir.
REYATAZ/ritonavir is coadministered with clarithromycin. 
REYATAZ/ritonavir primjenjuje istovremeno s klaritromicinom.
REYATAZ/ritonavir should be administered 2 hours before or 1 hour after antacids or buffered medicinal products. 
REYATAZ/ritonavira treba primijeniti 2 sata prije ili 1 sat nakon antacida i puferiranih lijekova.
REYATAZ (without ritonavir) has been studied in adult subjects with moderate-to-severe hepatic impairment (14 Child-Pugh Class B and 2 Child-Pugh Class C subjects) after a single 400 mg dose. 
REYATAZ (bez ritonavira) ispitivao se u odraslih ispitanika s umjerenim do teškim oštećenjem funkcije jetre (14 ispitanika s Child-Pugh stadijem B i 2 ispitanika s Child-Pugh stadijem C) nakon primjene jednokratne doze od 400 mg.
Withdrawal of ritonavir only under restrictive conditions The recommended standard treatment is REYATAZ boosted with ritonavir, ensuring optimal pharmacokinetic parameters and level of virologic suppression. 
Preporučeni standardni režim liječenja je REYATAZ pojačan ritonavirom, čime se osiguravaju optimalni farmakokinetički parametri i optimalna razina virološke supresije.
In paediatric patients with pre-existing conduction problems (second degree or higher atrioventricular or complex bundle-branch block), REYATAZ should be used with caution and only if the benefits exceed the risk. 
U pedijatrijskih bolesnika s već prisutnim poremećajem provođenja (atrioventrikularni blok drugog ili višeg stupnja ili kompletni blok grane) REYATAZ treba primjenjivati s oprezom i samo ako je korist veća od rizika.
Difference estimatee [95% CI] 
Procjena razlikee [95% CI]
b Number of patients evaluable. 
b Broj bolesnika koji se mogao procijeniti.
Each carton contains one high-density polyethylene (HDPE) bottle or three high-density polyethylene (HDPE) bottles closed with child-resistant polypropylene closure. 
Jedna kutija sadrži jednu bocu od polietilena visoke gustoće (HDPE) ili tri boce od polietilena visoke gustoće (HDPE), zatvorenu polipropilenskim zatvaračem sigurnim za djecu.
The most frequently reported laboratory abnormality in patients receiving regimens containing REYATAZ and one or more NRTIs was elevated total bilirubin reported predominantly as elevated indirect [unconjugated] bilirubin (87% Grade 1, 2, 3, or 4). 
Najčešće zabilježeni laboratorijski nalaz u bolesnika koji primaju terapiju lijekom REYATAZ i jednim ili više NRTI-jeva bio je povišen ukupni bilirubin zabilježen pretežno kao povišeni indirektni [nekonjugirani] bilirubin (87% 1., 2., 3. ili 4. stupnja).
Desacetyl-diltiazem AUC ↑165% Desacetyl-diltiazem Cmax ↑172% Desacetyl-diltiazem Cmin ↑121% 
Dezacetil-diltiazem AUC ↑165% Dezacetil-diltiazem Cmax ↑172% Dezacetil-diltiazem Cmin ↑121%
C: To mix the recommended number of REYATAZ oral powder sachets with food such as applesauce or yogurt in a small container: One tablespoon of food is used to mix the content of the sachets. 
C: Za miješanje preporučenog broja vrećica REYATAZ oralnog praška s hranom kao što je kašica od jabuke ili jogurt u malom spremniku: Jedna jušna žlica hrane koristi se da bi se promješao sadržaj vrećice.
Table 6: Efficacy Outcomes at Week 48a and at Week 96 (Study 045) 
Tablica 6: Ishodi djelotvornosti u 48. tjednua i 96. tjednu (Ispitivanje 045)
Protease inhibitor resistance was defined as genotypic resistance to atazanavir or either component of the local NRTI backbone based on the criteria of 1) any major mutations: I50L, I84V, N88S and 2) ≥ 2 of the following minor or cross resistant mutations: M46I/L, G48V, I54L/V/M/T/A, V82A/T/FI, L90M, V32I. 
Rezistencija na inhibitore proteaze definirana je kao genotipska rezistencija na atazanavir ili bilo koji lijek koji je dio osnovnog liječenja u ksladu s nacionalnim smjernicama koje se sastoji od NRTI-ja, temeljem kriterija 1) bilo koja velika mutacija: I50L, I84V, N88S i 2) ≥ 2 od sljedećih malih ili unakrsno rezistentnih mutacija M46I/L, G48V, I54L/V/M/T/A, V82A/T/FI, L90M, V32I.
If REYATAZ/ritonavir is coadministered with irinotecan, patients should be closely monitored for adverse events related to irinotecan. 
Ako se REYATAZ/ritonavir primjenjuje istovremeno s irinotekanom, bolesnike treba pažljivo pratiti zbog nuspojava povezanih s irinotekanom.
The residual mixture is drawn up into the syringe and administered into either the right or left inner cheek of the infant. 
Preostali dio mješavine uvuče se u štrcaljku i primjeni s unutarnje strane desnog ili lijevog obraza dojenčeta.
CD4 count <50 cells/mm3 
Broj CD4 stanica <50 stanica/mm3
The recommended adult dose of REYATAZ capsules is 300 mg once daily with 100 mg ritonavir once daily and with food, in combination with other anti-HIV medicines. 
Preporučena doza REYATAZ kapsula za odrasle je 300 mg jedanput na dan sa 100 mg ritonavira jedanput na dan i s hranom, u kombinaciji s drugim anti-HIV lijekovima.
The dose of REYATAZ oral powder for children is calculated by body weight and is taken once daily with food and ritonavir as shown below: 
Doza REYATAZ oralnog praška za djecu izračunava se na temelju tjelesne težine i uzima se jedanput na dan s hranom s ritonavirom na sljedeći način:
Among patients receiving REYATAZ 300 mg with ritonavir 100 mg, the frequency of jaundice was 19%. 
Među bolesnicima koji su primali REYATAZ 300 mg s ritonavirom 100 mg, učestalost žutice bila je 19%.
Rare (may affect up to 1 in 1,000 people): gait disturbance (abnormal manner of walking) oedema (swelling) hepatosplenomegaly (enlargement of the liver and spleen) myopathy (aching muscles, muscle tenderness of weakness, not caused by exercise) kidney pain 
Rijetko (mogu se javiti u do 1 na 1000 osoba): poremećaj hoda (abnormalan način hodanja) edemi (oticanje), hepatosplenomegalija (povećanje jetre i slezene) miopatija (bolni mišići, osjetljivost na dodir i slabost mišića, što nije prouzročeno vježbanjem) bubrežni bolovi
Didanosine (buffered tablets) 200 mg/stavudine 40 mg, both single dose (atazanavir 400 mg single dose) 
Didanozin (puferirane tablete) 200 mg/stavudin 40 mg, oba u jednokratnoj dozi (atazanavir 400 mg, jednokratna doza)
Consult the dosing table for the specific formulation (see Summary of Product Characteristics for REYATAZ oral powder). 
Provjerite tablicu doziranja za određenu formulaciju (vidjeti Sažetak opisa svojstava lijeka za REYATAZ oralni prašak).
Co-administration of a single 300 mg dose of REYATAZ and 100 mg dose of ritonavir with a light meal resulted in a 33% increase in the AUC and a 40% increase in both the Cmax and the 24 hour concentration of atazanavir relative to the fasting state. 
Istovremena primjena jednokratne doze lijeka REYATAZ od 300 mg i doze ritonavira od 100 mg uz lagani obrok rezultirala je povećanjem AUC-a za 33% i povećanjem Cmax i 24-satne koncentracije atazanavira za 40% u odnosu na primjenu natašte.
Patients with rare hereditary problems of fructose intolerance, glucose galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. 
Bolesnici s rijetkim nasljednim poremećajem nepodnošenja fruktoze, malapsorpcijom glukoze-galaktoze ili saharozaizomaltaza insuficijencijom ne smiju uzimati ovaj lijek.
Put the syringe tip into the mixture and pull back the plunger until the full amount of infant formula is taken up. 
Stavite vrh štrcaljke u smjesu i povucite klip sve dok se puna količina dječje formule nije uvukla.
When given with REYATAZ/ritonavir, the recommended dose of rifabutin is 150 mg 3 times per week on set days (for example MondayWednesday-Friday). 
Kad se daje s lijekom REYATAZ/ritonavira, preporučena doza rifabutina je 150 mg tri puta tjedno u određene dane (na primjer, ponedjeljak-srijeda-petak).
Paediatric patients (6 years to less than 18 years of age and weighing at least 15 kg) The dose of atazanavir capsules for paediatric patients is based on body weight as shown in Table 1 and should not exceed the recommended adult dose. 
Pedijatrijski bolesnici (u dobi od 6 godina do manje od 18 godina i tjelesne težine od najmanje 15 kg) Doza atazanavir kapsula za pedijatrijske bolesnike temelji se na tjelesnoj težini, kako je prikazano u tablici 1, i ne smije biti veća od preporučene doze za odrasle.
Each carton contains 30 x 1 capsules; 5 blister cards of 6 x 1 capsules each in Alu/Alu perforated unit dose blisters. 
Jedna kutija sadrži 30 x 1 kapsulu; 5 blister kartica sa 6 x 1 kapsulom u perforiranom Al/Al blisteru djeljivom na pojedinačne doze.
Rashes are usually mild-to-moderate maculopapular skin eruptions that occur within the first 3 weeks of starting therapy with REYATAZ. 
Osipi su obično blage do umjerene makulopapularne erupcije koje nastaju tijekom prva 3 tjedna od početka terapije lijekom REYATAZ.